Literature DB >> 12926068

cIAP-2 block apoptotic events in bladder cancer cells.

Gun Jönsson1, Staffan Paulie, Alf Grandien.   

Abstract

BACKGROUND: The Inhibitors of Apoptosis (IAPs) are negative regulators of apoptosis and their overexpression renders cells resistant to a variety of apoptotic stimuli. We investigated the mRNA expression levels of IAPs in a panel of bladder tumour cells, selected as being sensitive or resistant to death receptor-mediated apoptosis.
MATERIALS AND METHODS: The mRNA expression of IAPs was quantified in a RNase protection assay (RPA). Apoptosis was induced by recombinant killerTRAIL, agonistic anti-CD95 mAbs or doxorubicin and quantified by TUNEL and MTT assays. Stable expression of cIAP-2 was obtained by retroviral transduction.
RESULTS: The expression of cIAP-2 mRNA was highly correlated with resistance to TRAIL-mediated apoptosis. Overexpression of cIAP-2 conferred resistance to previously sensitive cell lines and made cells less susceptible to doxorubicin. Treatment with doxorubicin in combination with TRAIL or anti-CD95 resulted in a synergistic cytotoxic effect, which was not possible to reverse by overexpression of cIAP-2.
CONCLUSION: cIAP-2 is an important regulator of apoptosis in bladder cancer and its overexpression may make tumours less susceptible to therapy involving apoptosis. The combination of immunotherapy and chemotoxic agents may represent a valid strategy to potentiate anti-tumour therapy, in particular treating tumours resisting conventional chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12926068

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest.

Authors:  Hyung-Seung Jin; Tae H Lee
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

2.  Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL.

Authors:  Goodwin Jinesh G; Srinivas Chunduru; Ashish M Kamat
Journal:  J Leukoc Biol       Date:  2012-04-18       Impact factor: 4.962

3.  A new oncolytic adenoviral vector carrying dual tumour suppressor genes shows potent anti-tumour effect.

Authors:  Xin-Ran Liu; Ying Cai; Xin Cao; Rui-Cheng Wei; Hui-Ling Li; Xiu-Mei Zhou; Kang-Jian Zhang; Shuai Wu; Qi-Jun Qian; Biao Cheng; Kun Huang; Xin-Yuan Liu
Journal:  J Cell Mol Med       Date:  2012-06       Impact factor: 5.310

Review 4.  Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs).

Authors:  Rama Rathore; Jennifer E McCallum; Elizabeth Varghese; Ana-Maria Florea; Dietrich Büsselberg
Journal:  Apoptosis       Date:  2017-07       Impact factor: 4.677

Review 5.  Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.

Authors:  Vesna Risso; Elodie Lafont; Matthieu Le Gallo
Journal:  Cell Death Dis       Date:  2022-03-17       Impact factor: 9.685

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.